Enozertinib in EGFR Exon 20ins mutants: a game changer for CNS metastases, or a temporary conquest?

Naoki Furuya · 2026

Read Enozertinib in EGFR Exon 20ins mutants: a game changer for CNS metastases, or a temporary conquest? by Naoki Furuya (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13557853.txt.

Description

ns in vitro and in vivo preclinical models. Amivantamab in combination with carboplatin plus pemetrexed was established in the PAPILLON study for patients with EGFR Ex20ins as the first-line setting (2), and is strongly recommended in current guidelines (3). However, the PAPILLON regimen requires intravenous administration and involves complex management of adverse events (AEs).

Catalog record

CREATORNaoki Furuya
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE9 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13557853

Browse the full library · About the Tower of Babel